Study of medications for depression with suicidal thoughts
Part of Mental health clinical trials.
This research study tests different medication approaches for people with major depression who are having thoughts of suicide. The goal is to understand which treatments work best and why, so doctors can help patients more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with major depressive disorder (persistent sadness or loss of interest in activities)
- You are currently having thoughts of suicide or self-harm
- You completed at least primary school education
- You do not have other serious mental health conditions (like bipolar disorder, schizophrenia, or severe anxiety disorder)
- You have not used drugs or alcohol heavily in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if ketamine can help reduce suicidal thoughts in people with major depression. You'll receive ketamine treatment and be monitored closely.
This study tests how ketamine affects brain chemicals linked to suicidal thoughts in people with depression. You will receive ketamine and have brain scans (PET and MRI) to see if it changes activity in opioid receptors.
This study tests whether ketamine (a medication) combined with a specific type of therapy called DBT can help people with treatment-resistant depression and borderline personality disorder who are having thoughts of suicide. You would receive ketamine infusions alongside structured therapy sessions over 6 months.
This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.
This study tests a new type of brain stimulation called TMS (transcranial magnetic stimulation) for young people ages 15-25 who are having serious depression and suicidal thoughts. The goal is to see if this treatment can help reduce risk and improve mood.
This Phase 4 study tests whether ongoing treatment with ketamine or esketamine can reduce suicidal thoughts in people with major depression who are at high risk. Because the study focuses on long-term maintenance, you’d receive treatment over time while being closely monitored for safety and mental health changes.
Hear when a new Major Depressive Disorder (MDD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.